A Randomized, double blind study to determine the effect oftwo dose schedules of R1507 or placebo, both in combinationwith erlotinib (Tarceva), on progression-free survival inpatients with advanced non-small cell lung cancer with diseaseprogression after first or second line chemotherapy. - ND
- Conditions
- Clinical stage IIIb/IV Non-small cell lung cancer with diseaseprogression following at least one but no more than two standardchemotherapy regimensMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIB
- Registration Number
- EUCTR2008-001736-12-IT
- Lead Sponsor
- ROCHE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 150
1. Male and female patients, age >=18 years
2. Able to comply with the protocol
Patients must be able to take oral medication
4. Histologically documented inoperable, locally advanced or
metastatic (stage IIIB and stage IV) NSCLC. (NOTE: Sputum cytology alone is not acceptable). Tumors with mixed histology should be categorized according to the predominant cell type
5. Prior Treatment: Failed at least one, but no more than two standard chemotherapy regimens
6. Patients who have received maintenance chemotherapy between initial course of therapy (first line) and study entry may enter on the study provided they have not been treated
with an agent that targets EGFR or IGF-1R
7. Formalin fixed paraffin embedded tumor tissue samples from initial or subsequent diagnosis representative of the disease must be available for shipment to Roche prior to randomization
8. Measurable disease according to RECIST
9. ECOG performance status 0-2
10. Life expectancy > 12 weeks
11. Adequate hematological function : ANC >= 1.5 x 109/L;
platelets ≥100 x 109/L, Hb >= 9 g/dL
12. INR <=1.5 and PTT <=1.5 x ULN unless receiving
anticoagulant therapy
13. Adequate liver function: Serum bilirubin <=1.5 x ULN;
transaminases <=2.5 x ULN (in case of liver metastases <5 x
ULN)
14. Adequate renal function: Serum creatinine <=1.5 X ULN
15. Serum calcium <=1.1 X ULN
16. HbA1c <=7%
17. Negative pregnancy test within 7 days of starting study
treatment in pre-menopausal women and women < 2 years
after the onset of menopause
18. Signed informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
1. Patients must have had a head CT/MRI to evaluate for CNS metastasis within 28 days prior to enrollment. Patients with active CNS lesions are excluded. Patients with radiographically stable, asymptomatic previously irradiated lesions are eligible provided patients is >= 4 weeks beyond completing cranial irradiation and >=3 weeks off corticosteroid therapy
2. Prior treatment with an investigational or commercial agent
that acts via IGF-1R inhibition
3. Prior treatment with an agent that acts via EGFR targeting
4. Administration of any anti-cancer therapies other than those
administered in this study during protocol treatment
5. Administration of high doses of systemic corticosteroids.
High dose is considered as > 20 mg of dexamethasone a day (or equivalent) for > 7 consecutive days.
Dexamethasone may induce CYP3A4 activity. CYP3A4 inhibitors and inducers may influence the plasma level of erlotinib
6. Prior irradiation: 1) Radiotherapy given within the last 4 weeks prior to first dose of study treatment.
2) Palliative radiotherapy for bone lesions outside the thoracic region
within 2 weeks prior to the first dose of study treatment
7. Prior Surgery: Surgery (including open biopsy) or significant traumatic injury within the last 2 weeks prior to
first dose of study treatment or anticipation of the need for major surgery during study treatment
8. Patients must have recovered from any toxic effects of previously administered therapies and must be randomly assigned to study treatment at least 21 days after chemotherapy (14 days after treatment with vinca alkaloids or gemcitabine)
9. Lactating women
10. Fertile men or women of childbearing potential not using
effective methods to prevent pregnancy
11. Other active cancer requiring treatment
12. Known hypersensitivity to any of the study drugs or their excipients
13. Any disease (including psychotic disorders, drug abuse, active infection, uncontrolled hypertension, clinically significant cardiovascular disease for example CVA (<= 6 months before randomization), myocardial infarction (<= 6 months before randomization), unstable angina, NYHA >= grade 2 CHF, arrhythmia requiring medication, hepatic, renal or metabolic disease (including uncontrolled diabetes
mellitus), metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the
use of an investigational drug or puts the patient at high risk for treatment-related complications
14. History of allogeneic bone marrow transplantation or organ transplantation
Any known significant ophthalmologic abnormalities of the surface of the eye (the use of contact lenses is not
recommended)
16. No dysphagia or active gastrointestinal disease or disorder
that alters gastrointestinal motility or absorption; no lack of integrity of the gastrointestinal tract (e.g. as significant surgical resection of the stomach or small bowel). Patients
unable to swallow intact tablets must be able to swallow tablets dissolved in water
17. Treatment with any other investigational agent, or
participation in another clinical trial within 30 days prior to starting study treatment
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method